2 weeks Ago By ABMN Staff
CARGO Therapeutics, Inc. ( NASDAQ:CRGX – Get Free Report )’s share price traded down 6.2% during trading on Friday .
The stock traded as low as $17.19 and last traded at $17.34.
195,002 shares traded hands during trading, a decline of 28% from the average session volume of 271,312 shares. The stock had previously closed at $18.49.
Analyst Ratings Changes Several brokerages recently weighed in on CRGX. Piper Sandler decreased their price target on CARGO Therapeutics from $37.00 to $34.
00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of CARGO Therapeutics in a report on Tuesday, August 13th.
Finally, Chardan Capital initiated coverage on shares of CARGO Therapeutics in a research note on Monday, July 8th. They set a “buy” rating and a $28.00 price target on the stock.
Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CARGO Therapeutics presently has an average rating of “Buy” and an average price target of $30.33.
View Our Latest Research Report on CARGO Therapeutics CARGO Therapeutics Price Performance CARGO Therapeutics ( NASDAQ:CRGX – Get Free Report ) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.
06) by $0.04. Equities research analysts expect that CARGO Therapeutics, Inc.
will post -4.37 EPS for the current year. Insider Activity In related news, CEO Gina Chapman sold 2,975 shares of the company’s stock in a transaction that occurred on Thursday, September 19th.
The stock was sold at an average price of $25.03, for a total value of $74,464.25.
Following the sale, the chief executive officer now owns 103,905 shares in the company, valued at approximately $2,600,742.15. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink .
In other news, CEO Gina Chapman sold 2,975 shares of CARGO Therapeutics stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $25.03, for a total transaction of $74,464.
25. Following the completion of the transaction, the chief executive officer now owns 103,905 shares of the company’s stock, valued at approximately $2,600,742.15.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link . Also, CFO Anup Radhakrishnan sold 1,600 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $25.
28, for a total transaction of $40,448.00. Following the completion of the sale, the chief financial officer now owns 6,446 shares in the company, valued at $162,954.
88. The disclosure for this sale can be found here . Insiders own 1.
38% of the company’s stock. Institutional Trading of CARGO Therapeutics Several large investors have recently modified their holdings of CRGX. RTW Investments LP purchased a new stake in CARGO Therapeutics in the 4th quarter valued at approximately $119,821,000.
Perceptive Advisors LLC acquired a new position in CARGO Therapeutics in the 4th quarter valued at about $79,557,000. Wellington Management Group LLP acquired a new position in shares of CARGO Therapeutics in the fourth quarter valued at approximately $39,009,000. Yu Fan acquired a new position in shares of CARGO Therapeutics in the second quarter valued at approximately $14,975,000.
Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of CARGO Therapeutics by 38.2% during the first quarter.
Price T Rowe Associates Inc. MD now owns 3,093,347 shares of the company’s stock valued at $69,044,000 after buying an additional 854,840 shares during the period. 93.
16% of the stock is currently owned by institutional investors and hedge funds. About CARGO Therapeutics ( Get Free Report ) CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Featured Articles Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
